Goldman Sachs analyst Salveen Richter keeps a Buy rating and $1,060 price target on Regeneron following yesterday’s U.S. District Court judgment on the litigation between Regeneron and Viatris/Biocon regarding three patents related to Eylea 2mg and pertaining to market entry of the latter’s biosimilar. The judgment is a net positive for Regeneron given the win on all litigated claims on the formulation patent ‘865, which expires on June 14, 2027, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron rises after ruling in patent fight with Viatris
- Regeneron (NASDAQ:REGN) Gains after Patent Suit Mostly Wins
- Regeneron VP Fenimore sells $1.6M in company shares
- Regeneron price target raised to $1,125 from $1,050 at Oppenheimer
- Regeneron’s treatment of Hemophilia B granted FDA orphan designation